Patent intelligence · US
US 11642366
Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
Patent details — US 11642366
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 9, 2023
- Expiration
- May 4, 2043
- Applicant
- GLYCOMIRA THERAPEUTICS, INC.
- Claims
- 26
- CPC classes
- A61K, A61K31/727, A61K31/728, A61K31/737
Quick answer
US 11642366 (Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy) is held by GLYCOMIRA THERAPEUTICS, INC.. Status: granted. Granted May 9, 2023. Expires May 4, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GLYCOMIRA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/727, A61K31/728, A61K31/737, A61K45/06, A61P
More from GLYCOMIRA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 11642366?
US 11642366 (Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy) is held by GLYCOMIRA THERAPEUTICS, INC.. Status: granted. Granted May 9, 2023. Expires May 4, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11642366?
GLYCOMIRA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 11642366 expire?
Our index shows an expiration date of May 4, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.